Gold bars to be exempt from tariffs, White House clarifies
On Wednesday, Benchmark analyst Josh Sullivan confirmed a Buy rating on Ultralife Corporation (NASDAQ:ULBI) with a consistent price target of $14.00, representing significant upside from the current price of $6.12. Sullivan’s endorsement follows Ultralife’s first-quarter performance, which surpassed expectations, marking the initial period incorporating results from the recently acquired Electrochem Solutions. According to InvestingPro data, the stock has shown strong momentum with a 13.45% return over the past week, though it remains significantly below its 52-week high of $12.40.
Ultralife reported a significant 32% year-over-year increase in revenues, with approximately 11% of that growth being organic. The company’s EBITDA reached $14.03 million, exceeding analyst projections, while maintaining a healthy gross profit margin of 25.19%. The integration of Electrochem Solutions is on track for completion in the second quarter of 2025, with the implementation of an Enterprise Resource Planning (ERP) system as a key milestone. InvestingPro analysis indicates the company maintains strong financial health with a current ratio of 3.22, suggesting robust liquidity to support its integration efforts.
The acquisition has already enhanced Ultralife’s battery pack assembly capabilities and facilitated entry into new markets, including pipeline inspection, seismic telemetry, and sonobuoys. Ultralife is also advancing its gross margins through strategic pricing, material cost management, and lean productivity initiatives, which featured the closure of a smaller facility within the first quarter of 2025.
Sullivan highlighted that Ultralife’s Thin-cell technology for medical wearables is poised for significant growth, especially since its partner received FDA approval in the fourth quarter of 2024. This development is expected to lead to substantial orders for Ultralife in the current year, with InvestingPro forecasting a 29% revenue growth for FY2025. The company is also making headway with its ruggedized high-performance non-rechargeable (HP-NR) server cases. For deeper insights into Ultralife’s growth potential and comprehensive analysis, investors can access the detailed Pro Research Report, available exclusively to InvestingPro subscribers.
The analyst pointed out Ultralife’s strategic moves post-COVID, which have increased scale and capacity. The addition of Electrochem’s assets has already started to improve margins and is anticipated to further enhance profitability as volumes return. In summary, Sullivan expects Ultralife’s medical wearable technology to secure more orders this year, the Electrochem integration to conclude soon, and the server case venture to keep progressing.
In other recent news, Ultralife Corporation reported its Q1 2025 earnings, showing a revenue of $50.7 million, which surpassed the forecast of $48 million. Despite this revenue beat, the company’s earnings per share (EPS) fell short, coming in at $0.11 compared to the expected $0.14. The strong revenue performance was driven by a 53.6% increase in government defense sales, though the company faced challenges in its Communications Systems (NASDAQ:SUNE) division, where revenue declined significantly. Analysts noted the company’s ongoing focus on new product development and international market expansion as potential drivers for future growth. During the earnings call, Ultralife management highlighted the successful integration of their recent acquisition, Electrochem, which contributed positively to the quarter. The company is optimistic about a recovery in medical battery sales in the latter half of 2025. Additionally, Ultralife is implementing strategies to mitigate the impact of tariffs on its operations. The firm remains committed to improving its gross margins and leveraging vertical integration opportunities stemming from the Electrochem acquisition.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.